慢性阻塞性肺疾病患者的COVID-19疫苗接种覆盖率——匈牙利一项横断面研究
该研究为在匈牙利东部、西部和中部地区开展的横断面观察性研究(CHANCE),纳入1511例35岁及以上随机选择的COPD患者,记录人体测量、呼吸功能测试结果和疫苗接种状态。研究自2021年11月15日开始,旨在评估COVID-19大流行第一轮疫苗接种活动期间COPD患者的COVID-19疫苗接种覆盖率。
要点
- 第一剂COVID-19疫苗覆盖率为88.62%,第二剂为86.57%。
- 未接种组与双重接种组在生活质量(CAT评分)和呼吸困难严重程度(mMRC评分)上差异显著。
- 接种后6个月,双重接种组与未接种组COVID-19感染率分别为1.61% vs 22.67%(p < 0.001)。
核心结论
- 样本中COVID-19疫苗接种覆盖率令人满意;COPD患者接种COVID-19疫苗至关重要,因其更易出现严重并发症。
研究设计与样本
- 横断面观察性研究(CHANCE),在匈牙利东部、西部和中部地区开展,自2021年11月15日开始。
- 纳入1511例35岁及以上随机选择的COPD患者,记录人体测量、呼吸功能测试结果和疫苗接种状态。
主要发现
- 中位年龄67(61-72)岁,男性67(62-73)岁,女性66(60-72)岁;男性占47.98%,女性占52.02%。
- 第一剂COVID-19疫苗覆盖率为88.62%,第二剂为86.57%。
- 未接种组(n=172)与双重接种组(n=1308)比较:生活质量CAT评分17(12-23) vs 14(10-19),p < 0.001;呼吸困难严重程度mMRC评分2(2-2) vs 2(1-2),p = 0.048。
- 接种后6个月,双重接种组与未接种组COVID-19感染率分别为1.61% vs 22.67%,p < 0.001。
- 急性COVID-19感染住院者中,未接种组与接种组分别为8.14% vs 0.08%,p < 0.001。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Coronavirus infection is a particular risk for patients with chronic obstructive pulmonary disease (COPD), because they are much more likely to become severely ill due to oxygen supply problems. Primary prevention, including COVID-19 vaccination is of paramount importance in this disease group. The aim of our study was to assess COVID-19 vaccination coverage in COPD patients during the first vaccination campaign of the COVID-19 pandemic. METHODS: A cross-sectional observational study (CHANCE) has been conducted in COPD patients in the eastern, western and central regions of Hungary from 15th November 2021. The anthropometric, respiratory function test results and vaccination status of 1,511 randomly selected patients were recorded who were aged 35 years and older. RESULTS: The median age was 67 (61-72) years, for men: 67 (62-73) and for women: 66 (60-72) years, with 47.98 % men and 52.02 % women in our sample. The prevalence of vaccination coverage for the first COVID-19 vaccine dose was 88.62 %, whereas 86.57 % of the patients received the second vaccine dose. When unvaccinated (n = 172) and double vaccinated (n = 1308) patients were compared, the difference was significant both in quality of life (CAT: 17 (12-23) vs 14 (10-19); p < 0.001) and severity of dyspnea (mMRC: 2 (2-2) vs 2 (1-2); p = 0.048). The COVID-19 infection rate between double vaccinated and unvaccinated patients was 1.61 % vs 22.67 %; p < 0.001 six months after vaccination. The difference between unvaccinated and vaccinated patients was significant (8.14 % vs 0.08 %; p < 0.001) among those with acute COVID-19 infection hospitalized. In terms of post-COVID symptoms, single or double vaccinated patients had significantly fewer outpatient hospital admissions than unvaccinated patients (7.56 vs 0 %; p < 0.001). CONCLUSION: The COVID-19 vaccination coverage was satisfactory in our sample. The uptake of COVID-19 vaccines by patients with COPD is of utmost importance because they are much more likely to develop severe complications.
引用
- Fekete M, Horvath A, Santa B, et al. COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease - A cross-sectional study in Hungary. Vaccine. 2022. PMID: 36424256. doi:10.1016/j.vaccine.2022.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。